A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk ...

First teased in June and formally announced Tuesday as part of “Operation Trialblazer,” the program will partner drugmakers ...

As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings ...

Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course ...

Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality ...

One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key ...

Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.

Projected by some analysts as a future blockbuster, Isembyld is the first “muscle-targeted” treatment for the disease and, in ...

Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche ...

AI is evolving from interactive chats to automated workloads driven by agentic tools, compressing timelines and enabling faster outcomes. A new reference architecture running on the Dell Pro Max with ...

The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s ...

Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of ...